X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (711) 711
chlorambucil (499) 499
chlorambucil - pharmacology (493) 493
animals (449) 449
female (331) 331
male (294) 294
pharmacology & pharmacy (249) 249
index medicus (227) 227
oncology (216) 216
mice (201) 201
antineoplastic agents - pharmacology (182) 182
middle aged (174) 174
aged (158) 158
chlorambucil - therapeutic use (158) 158
rats (155) 155
leukemia, lymphocytic, chronic, b-cell - drug therapy (137) 137
adult (134) 134
chlorambucil - administration & dosage (129) 129
cell survival - drug effects (118) 118
cancer (114) 114
antineoplastic agents, alkylating - pharmacology (109) 109
biochemistry & molecular biology (108) 108
dose-response relationship, drug (103) 103
tumor cells, cultured (102) 102
antineoplastic combined chemotherapy protocols - therapeutic use (101) 101
chemistry, medicinal (101) 101
cell line, tumor (97) 97
drug resistance (90) 90
chlorambucil - chemistry (87) 87
chlorambucil - metabolism (84) 84
hematology (84) 84
time factors (80) 80
cyclophosphamide (79) 79
chlorambucil - analogs & derivatives (78) 78
kinetics (78) 78
rituximab (77) 77
apoptosis (76) 76
antineoplastic agents - therapeutic use (75) 75
chronic lymphocytic leukemia (73) 73
leukemia, lymphocytic, chronic, b-cell - pathology (71) 71
cells, cultured (69) 69
cytotoxicity (69) 69
fludarabine (69) 69
therapy (69) 69
vidarabine - analogs & derivatives (69) 69
antineoplastic agents (68) 68
chronic lymphocytic-leukemia (67) 67
cyclophosphamide - pharmacology (67) 67
apoptosis - drug effects (66) 66
dna (66) 66
melphalan - pharmacology (66) 66
structure-activity relationship (66) 66
expression (65) 65
chemotherapy (63) 63
drug screening assays, antitumor (63) 63
in vitro techniques (63) 63
leukemia (62) 62
nitrogen mustard compounds - pharmacology (62) 62
toxicology (59) 59
aged, 80 and over (58) 58
cell line (58) 58
alkylation (57) 57
in-vitro (55) 55
research (55) 55
melphalan (54) 54
alkylating agents - pharmacology (53) 53
treatment outcome (53) 53
cells (52) 52
pharmacology (52) 52
pharmacology/toxicology (52) 52
alkylating agents (49) 49
antineoplastic agents - chemistry (49) 49
drug synergism (49) 49
nitrogen mustards (49) 49
cell division - drug effects (48) 48
chlorambucil - toxicity (48) 48
lymphocytes - drug effects (48) 48
antimitotic agents (47) 47
antineoplastic agents - chemical synthesis (47) 47
chemistry, multidisciplinary (46) 46
medicine & public health (46) 46
resistance (46) 46
drugs (45) 45
cyclophosphamide - administration & dosage (44) 44
cell proliferation - drug effects (43) 43
chlorambucil - adverse effects (43) 43
care and treatment (41) 41
glutathione transferase - metabolism (41) 41
pharmacokinetics (41) 41
alkylating-agents (40) 40
chemistry, organic (40) 40
molecular structure (40) 40
drug resistance, neoplasm (39) 39
hydrogen-ion concentration (38) 38
antineoplastic agents, alkylating - chemistry (37) 37
chlorambucil - chemical synthesis (37) 37
drug-resistance (37) 37
mechlorethamine - pharmacology (37) 37
prognosis (37) 37
antineoplastic combined chemotherapy protocols - adverse effects (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1208) 1208
French (21) 21
German (15) 15
Russian (15) 15
Italian (8) 8
Japanese (5) 5
Polish (4) 4
Portuguese (2) 2
Spanish (2) 2
Chinese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | GENE-MUTATIONS | LUNG-CANCER | FUNCTIONAL-ACTIVITY | ONCOLOGY | ABL TYROSINE KINASE | MITOMYCIN-C | PANCREATIC-CANCER | RANDOMIZED-TRIAL | PHASE-II | COMPLEMENTATION GROUP | CARCINOMA | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology
Journal Article
Free Radical Biology and Medicine, ISSN 0891-5849, 2005, Volume 39, Issue 5, pp. 696 - 703
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 11/2017, Volume 56, Issue 11, pp. 1255 - 1266
Management of chronic lymphocytic leukemia has changed markedly over the last several years with the emergence of several novel oral agents targeting B-cell... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TARGETED THERAPY | 1ST-LINE TREATMENT | PLUS CHLORAMBUCIL | 1ST GLOBAL APPROVAL | ANTI-CD20 MONOCLONAL-ANTIBODIES | IMPAIR ANTITUMOR-ACTIVITY | B-CELL MALIGNANCIES | TYROSINE KINASE INHIBITOR | NON-HODGKINS-LYMPHOMA | PHARMACOLOGY & PHARMACY | ANTIGEN RECEPTOR | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Drug Interactions | Antineoplastic Agents - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Purines - adverse effects | Purines - therapeutic use | Pyrazoles - pharmacokinetics | Quinazolinones - pharmacology | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Quinazolinones - pharmacokinetics | Purines - pharmacology | Food-Drug Interactions | Purines - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Parenteral therapy | Chronic lymphocytic leukemia | Care and treatment | Usage | Analysis | Parenteral feeding | Pharmacology | Pharmacokinetics | Lymphocyte receptors | Chemotherapy | Leukemia | Clinical trials | Lymphomas | FDA approval | Patients | Drug dosages | Index Medicus
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 08/2014, Volume 136, Issue 33, pp. 11748 - 11756
All drugs for cancer therapy face several transportation barriers on their tortuous journey to the action sites. To overcome these barriers, an effective drug... 
NANOPARTICLES | POLYMERS | EFFICACY | VESICLES | TUMOR | NANOMEDICINE | AGENTS | NANOCAPSULES | COPOLYMER MICELLES | CHEMISTRY, MULTIDISCIPLINARY | Prodrugs - administration & dosage | Small Molecule Libraries - pharmacology | Nanoparticles - chemistry | Apoptosis - drug effects | Small Molecule Libraries - administration & dosage | Drug Resistance, Multiple - drug effects | Humans | Prodrugs - chemistry | Chlorambucil - pharmacology | MCF-7 Cells | Mammary Neoplasms, Experimental - pathology | Molecular Structure | Iridium - chemistry | Mammary Neoplasms, Experimental - drug therapy | Chlorambucil - chemistry | Rats | Breast Neoplasms - drug therapy | Surface-Active Agents - pharmacology | Small Molecule Libraries - chemistry | Animals | Surface-Active Agents - administration & dosage | Breast Neoplasms - pathology | Mice, Nude | Organometallic Compounds - chemical synthesis | Organometallic Compounds - chemistry | Cell Proliferation - drug effects | Mice | Nanoparticles - administration & dosage | Surface-Active Agents - chemistry | Cell Cycle - drug effects | Surface-Active Agents - chemical synthesis | Drug Delivery Systems - methods | Prodrugs - pharmacology | Organometallic Compounds - pharmacology | Drug Resistance, Neoplasm - drug effects | Organometallic Compounds - administration & dosage | Drugs | Drug delivery systems | Care and treatment | Prodrugs | Dosage and administration | Research | Methods | Cancer | Vehicles
Journal Article
Experimental Hematology, ISSN 0301-472X, 2017, Volume 52, pp. 65 - 71
Drug interactions may dictate the failure or success of a treatment. Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various... 
Hematology, Oncology and Palliative Medicine | Advanced Basic Science | MEDICINE, RESEARCH & EXPERIMENTAL | BUSULFAN PHARMACOKINETICS | CELLS | THERAPY | CYTO-TOXICITY | GLUTATHIONE | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | MELPHALAN ACTIVITY | MYELOID-LEUKEMIA | MULTIDRUG-RESISTANCE | HEMATOLOGY | Cyclophosphamide - analogs & derivatives | Flow Cytometry - methods | Fluoresceins - metabolism | Humans | Ethacrynic Acid - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Chlorambucil - pharmacology | Ketoconazole - pharmacology | Drug Interactions | Everolimus - pharmacokinetics | Ethacrynic Acid - pharmacokinetics | Biological Transport - drug effects | Melphalan - pharmacology | Busulfan - pharmacology | Cell Survival - drug effects | Fluoresceins - chemistry | Reproducibility of Results | Busulfan - pharmacokinetics | Everolimus - pharmacology | Chlorambucil - pharmacokinetics | Ketoconazole - pharmacokinetics | Antineoplastic Agents, Alkylating - pharmacokinetics | Sirolimus - pharmacokinetics | Sirolimus - pharmacology | Cyclophosphamide - pharmacology | Cell Line, Tumor | Melphalan - pharmacokinetics | Cyclophosphamide - pharmacokinetics | Multidrug Resistance-Associated Proteins - metabolism | Antimitotic agents | Complications and side effects | Chemotherapy | Leukemia | Drug interactions | Lymphomas | Transplantation | Drug therapy, Combination | Antineoplastic agents | Ethacrynic acid | Hematopoietic stem cells | Cancer | flow cytometry | drug interactions | carboxyfluorescein | drug transporter | drug efflux method | stem cell transplantation
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, pp. 01 - 17
Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of... 
METASTATIC MELANOMA | TUMOR PH | INDUCED ACIDIFICATION | IN-VITRO | MAGNETIC-RESONANCE-SPECTROSCOPY | MULTIDISCIPLINARY SCIENCES | INTRACELLULAR PH | BRAF | DNA-SEQUENCING DATA | EXTRACELLULAR PH | CANCER | Cell Survival - drug effects | Alkylating Agents - pharmacology | Humans | Male | Melanoma - pathology | Chlorambucil - pharmacology | Mice, SCID | Mechlorethamine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Synergism | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Melanoma - drug therapy | Cell Line, Tumor | Melphalan - pharmacology | Mice | Doxorubicin - pharmacology | Complications and side effects | Care and treatment | Cyclophosphamide | Alkylating agents | Melanoma | Dosage and administration | Research | Potentiation | Animal models | Nuclear magnetic resonance--NMR | DNA alkyltransferase | Toxicity | Acidification | Metastasis | pH effects | DNA repair | Cancer therapies | Doxorubicin | Alkylation | Chlorambucil | Bioenergetics | Glutathione transferase | Spectrum analysis | Melphalan | Xenografts | pH | Inhibition | Deoxyribonucleic acid--DNA | Glutathione | Multidrug resistance | Nitrogen | Metabolism | Medicine | Acids | Mustard | Intracellular | Mutation | Tumors | Cancer | Index Medicus | Deoxyribonucleic acid | Nuclear magnetic resonance | NMR | DNA
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2012, Volume 7, Issue 9, p. e44330
Journal Article
Journal Article
Journal Article
Journal Article